Plethora Solutions’ latest update on its key treatment is “huge news”, chief executive Ronald Openshaw told Proactive Investors.
Only registred members can create thier own customized alerts.
Plethora is focussed on the development and marketing of products for the treatment of urological disorders. The Company is focussed on: (i) seeking to increase the value of its development assets the most advanced of which is PSD502 for the treatment of premature ejaculation; and (ii) driving the development of its speciality sales and marketing business, The Urology Company
Plethora’s subsidiary, The Urology Company Limited, established in 2009, markets and distributes a range of branded and generic pharmaceutical products, pharmaceutical specials, medical devices and nutritional supplements for the treatment of urology, and obstetric conditions. Its products fall into two categories (i) Professional – where a physician, nurse or other healthcare professional makes a prescribing decision and (ii) Consumer – where the consumer/patient makes a buying decision.